Skip to main content
Top
Published in: Virology Journal 1/2008

Open Access 01-12-2008 | Research

Isolation and characterization of cidofovir resistant vaccinia viruses

Authors: Marie N Becker, Maria Obraztsova, Earl R Kern, Debra C Quenelle, Kathy A Keith, Mark N Prichard, Ming Luo, Richard W Moyer

Published in: Virology Journal | Issue 1/2008

Login to get access

Abstract

Background

The emergence of drug resistant viruses, together with the possibility of increased virulence, is an important concern in the development of new antiviral compounds. Cidofovir (CDV) is a phosphonate nucleotide that is approved for use against cytomegalovirus retinitis and for the emergency treatment of smallpox or complications following vaccination. One mode of action for CDV has been demonstrated to be the inhibition of the viral DNA polymerase.

Results

We have isolated several CDV resistant (CDVR) vaccinia viruses through a one step process, two of which have unique single mutations within the DNA polymerase. An additional resistant virus isolate provides evidence of a second site mutation within the genome involved in CDV resistance. The CDVR viruses were 3–7 fold more resistant to the drug than the parental viruses. The virulence of the CDVR viruses was tested in mice inoculated intranasally and all were found to be attenuated.

Conclusion

Resistance to CDV in vaccinia virus can be conferred individually by at least two different mutations within the DNA polymerase gene. Additional genes may be involved. This one step approach for isolating resistant viruses without serial passage and in the presence of low doses of drug minimizes unintended secondary mutations and is applicable to other potential antiviral agents.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parker S, Nuara A, Buller RM, Schultz DA: Human monkeypox: an emerging zoonotic disease. Future Microbiol 2007, 2: 17-34. 10.2217/17460913.2.1.17CrossRefPubMed Parker S, Nuara A, Buller RM, Schultz DA: Human monkeypox: an emerging zoonotic disease. Future Microbiol 2007, 2: 17-34. 10.2217/17460913.2.1.17CrossRefPubMed
2.
go back to reference Adams MM, Rice AD, Moyer RW: Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J Virol 2007, 81: 11084-11095. 10.1128/JVI.00423-07PubMedCentralCrossRefPubMed Adams MM, Rice AD, Moyer RW: Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J Virol 2007, 81: 11084-11095. 10.1128/JVI.00423-07PubMedCentralCrossRefPubMed
3.
go back to reference Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY: Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318: 474-481. 10.1016/j.virol.2003.11.015CrossRefPubMed Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY: Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318: 474-481. 10.1016/j.virol.2003.11.015CrossRefPubMed
4.
go back to reference Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER: Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004, 48: 404-412. 10.1128/AAC.48.2.404-412.2004PubMedCentralCrossRefPubMed Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER: Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004, 48: 404-412. 10.1128/AAC.48.2.404-412.2004PubMedCentralCrossRefPubMed
5.
go back to reference Andrei G, Gammon DB, Fiten P, De CE, Opdenakker G, Snoeck R, Evans DH: Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J Virol 2006, 80: 9391-9401. 10.1128/JVI.00605-06PubMedCentralCrossRefPubMed Andrei G, Gammon DB, Fiten P, De CE, Opdenakker G, Snoeck R, Evans DH: Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J Virol 2006, 80: 9391-9401. 10.1128/JVI.00605-06PubMedCentralCrossRefPubMed
6.
go back to reference Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW: Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 2002, 46: 1329-1335. 10.1128/AAC.46.5.1329-1335.2002PubMedCentralCrossRefPubMed Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW: Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 2002, 46: 1329-1335. 10.1128/AAC.46.5.1329-1335.2002PubMedCentralCrossRefPubMed
7.
go back to reference Kornbluth RS, Smee DF, Sidwell RW, Snarsky V, Evans DH, Hostetler KY: Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob Agents Chemother 2006, 50: 4038-4043. 10.1128/AAC.00380-06PubMedCentralCrossRefPubMed Kornbluth RS, Smee DF, Sidwell RW, Snarsky V, Evans DH, Hostetler KY: Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob Agents Chemother 2006, 50: 4038-4043. 10.1128/AAC.00380-06PubMedCentralCrossRefPubMed
8.
go back to reference Smee DF, Wandersee MK, Bailey KW, Hostetler KY, Holy A, Sidwell RW: Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir Chem Chemother 2005, 16: 203-211.CrossRefPubMed Smee DF, Wandersee MK, Bailey KW, Hostetler KY, Holy A, Sidwell RW: Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir Chem Chemother 2005, 16: 203-211.CrossRefPubMed
9.
go back to reference Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR, Hostetler KY: Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002, 46: 991-995. 10.1128/AAC.46.4.991-995.2002PubMedCentralCrossRefPubMed Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR, Hostetler KY: Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002, 46: 991-995. 10.1128/AAC.46.4.991-995.2002PubMedCentralCrossRefPubMed
10.
go back to reference Buller RM, Smith GL, Cremer K, Notkins AL, Moss B: Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985, 317: 813-815. 10.1038/317813a0CrossRefPubMed Buller RM, Smith GL, Cremer K, Notkins AL, Moss B: Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985, 317: 813-815. 10.1038/317813a0CrossRefPubMed
11.
go back to reference Prichard MN, Keith KA, Johnson MP, Harden EA, McBrayer A, Luo M, Qiu S, Chattopadhyay D, Fan X, Torrence PF, Kern ER: Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob Agents Chemother 2007, 51: 1795-1803. 10.1128/AAC.01447-06PubMedCentralCrossRefPubMed Prichard MN, Keith KA, Johnson MP, Harden EA, McBrayer A, Luo M, Qiu S, Chattopadhyay D, Fan X, Torrence PF, Kern ER: Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob Agents Chemother 2007, 51: 1795-1803. 10.1128/AAC.01447-06PubMedCentralCrossRefPubMed
12.
go back to reference Condit RC, Motyczka A: Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus. Virology 1981, 113: 224-241. 10.1016/0042-6822(81)90150-1CrossRefPubMed Condit RC, Motyczka A: Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus. Virology 1981, 113: 224-241. 10.1016/0042-6822(81)90150-1CrossRefPubMed
13.
go back to reference Rybak RJ, Hartline CB, Qiu YL, Zemlicka J, Harden E, Marshall G, Sommadossi JP, Kern ER: In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections. Antimicrob Agents Chemother 2000, 44: 1506-1511. 10.1128/AAC.44.6.1506-1511.2000PubMedCentralCrossRefPubMed Rybak RJ, Hartline CB, Qiu YL, Zemlicka J, Harden E, Marshall G, Sommadossi JP, Kern ER: In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections. Antimicrob Agents Chemother 2000, 44: 1506-1511. 10.1128/AAC.44.6.1506-1511.2000PubMedCentralCrossRefPubMed
14.
go back to reference Chakrabarti S, Sisler JR, Moss B: Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997, 23: 1094-1097.PubMed Chakrabarti S, Sisler JR, Moss B: Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997, 23: 1094-1097.PubMed
15.
go back to reference Luttge BG, Moyer RW: Suppressors of a host range mutation in the rabbitpox virus serpin SPI-1 map to proteins essential for viral DNA replication. J Virol 2005, 79: 9168-9179. 10.1128/JVI.79.14.9168-9179.2005PubMedCentralCrossRefPubMed Luttge BG, Moyer RW: Suppressors of a host range mutation in the rabbitpox virus serpin SPI-1 map to proteins essential for viral DNA replication. J Virol 2005, 79: 9168-9179. 10.1128/JVI.79.14.9168-9179.2005PubMedCentralCrossRefPubMed
16.
go back to reference Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A: Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000, 29: 291-325. 10.1146/annurev.biophys.29.1.291CrossRefPubMed Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A: Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000, 29: 291-325. 10.1146/annurev.biophys.29.1.291CrossRefPubMed
17.
go back to reference Taddie JA, Traktman P: Genetic characterization of the vaccinia virus DNA polymerase: identification of point mutations conferring altered drug sensitivities and reduced fidelity. J Virol 1991, 65: 869-879.PubMedCentralPubMed Taddie JA, Traktman P: Genetic characterization of the vaccinia virus DNA polymerase: identification of point mutations conferring altered drug sensitivities and reduced fidelity. J Virol 1991, 65: 869-879.PubMedCentralPubMed
18.
go back to reference Taddie JA, Traktman P: Genetic characterization of the vaccinia virus DNA polymerase: cytosine arabinoside resistance requires a variable lesion conferring phosphonoacetate resistance in conjunction with an invariant mutation localized to the 3'-5' exonuclease domain. J Virol 1993, 67: 4323-4336.PubMedCentralPubMed Taddie JA, Traktman P: Genetic characterization of the vaccinia virus DNA polymerase: cytosine arabinoside resistance requires a variable lesion conferring phosphonoacetate resistance in conjunction with an invariant mutation localized to the 3'-5' exonuclease domain. J Virol 1993, 67: 4323-4336.PubMedCentralPubMed
19.
go back to reference DeFilippes FM: Site of the base change in the vaccinia virus DNA polymerase gene which confers aphidicolin resistance. J Virol 1989, 63: 4060-4063.PubMedCentralPubMed DeFilippes FM: Site of the base change in the vaccinia virus DNA polymerase gene which confers aphidicolin resistance. J Virol 1989, 63: 4060-4063.PubMedCentralPubMed
Metadata
Title
Isolation and characterization of cidofovir resistant vaccinia viruses
Authors
Marie N Becker
Maria Obraztsova
Earl R Kern
Debra C Quenelle
Kathy A Keith
Mark N Prichard
Ming Luo
Richard W Moyer
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2008
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-5-58

Other articles of this Issue 1/2008

Virology Journal 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.